Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury.

Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E.

J Neuroinflammation. 2013 Jul 23;10:91. doi: 10.1186/1742-2094-10-91. Erratum in: J Neuroinflammation. 2016;13(1):128.

2.

Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation.

Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M, Cuzzocrea S, Esposito E.

CNS Neurol Disord Drug Targets. 2014;13(9):1530-41.

PMID:
25106636
3.

Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.

Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S.

J Neuroinflammation. 2013 Feb 1;10:20. doi: 10.1186/1742-2094-10-20.

4.

Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man.

Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, Esposito E, Cuzzocrea S; Stroke Study Group.

Transl Stroke Res. 2016 Feb;7(1):54-69. doi: 10.1007/s12975-015-0440-8. Epub 2015 Dec 26.

5.

N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.

Skaper SD, Facci L, Barbierato M, Zusso M, Bruschetta G, Impellizzeri D, Cuzzocrea S, Giusti P.

Mol Neurobiol. 2015 Oct;52(2):1034-42. doi: 10.1007/s12035-015-9253-8. Epub 2015 Jun 9. Review.

PMID:
26055231
6.

Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury.

Cordaro M, Impellizzeri D, Paterniti I, Bruschetta G, Siracusa R, De Stefano D, Cuzzocrea S, Esposito E.

J Neurotrauma. 2016 Jan 1;33(1):132-46. doi: 10.1089/neu.2014.3460. Epub 2015 May 14.

PMID:
25046306
7.

Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury.

Crupi R, Impellizzeri D, Bruschetta G, Cordaro M, Paterniti I, Siracusa R, Cuzzocrea S, Esposito E.

Front Pharmacol. 2016 Mar 8;7:47. doi: 10.3389/fphar.2016.00047. eCollection 2016.

8.

Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice.

Impellizzeri D, Esposito E, Di Paola R, Ahmad A, Campolo M, Peli A, Morittu VM, Britti D, Cuzzocrea S.

Arthritis Res Ther. 2013;15(6):R192. Erratum in: Arthritis Res Ther. 2016;18(1):101.

9.

Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression.

Crupi R, Paterniti I, Ahmad A, Campolo M, Esposito E, Cuzzocrea S.

CNS Neurol Disord Drug Targets. 2013 Nov;12(7):989-1001.

PMID:
23844686
10.

The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model.

Siracusa R, Paterniti I, Impellizzeri D, Cordaro M, Crupi R, Navarra M, Cuzzocrea S, Esposito E.

CNS Neurol Disord Drug Targets. 2015;14(10):1350-65.

PMID:
26295827
11.

Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury.

Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S.

J Pharmacol Exp Ther. 2008 Jul;326(1):12-23. doi: 10.1124/jpet.108.136903. Epub 2008 Mar 26.

12.

Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury.

Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S.

Brain Behav Immun. 2011 Aug;25(6):1099-112. doi: 10.1016/j.bbi.2011.02.006. Epub 2011 Feb 25.

PMID:
21354467
13.

The Association of Palmitoylethanolamide with Luteolin Decreases Autophagy in Spinal Cord Injury.

Siracusa R, Paterniti I, Bruschetta G, Cordaro M, Impellizzeri D, Crupi R, Cuzzocrea S, Esposito E.

Mol Neurobiol. 2016 Aug;53(6):3783-3792. doi: 10.1007/s12035-015-9328-6. Epub 2015 Jul 5.

14.

A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation.

Esposito E, D I, G B, M C, R S, E G, R C, S C.

Eur J Pharmacol. 2016 Jul 5;782:107-18. doi: 10.1016/j.ejphar.2016.03.033. Epub 2016 Apr 16.

PMID:
27095683
15.

Evidence for the role of PI(3) -kinase-AKT-eNOS signalling pathway in secondary inflammatory process after spinal cord compression injury in mice.

Paterniti I, Esposito E, Mazzon E, Bramanti P, Cuzzocrea S.

Eur J Neurosci. 2011 Apr;33(8):1411-20. doi: 10.1111/j.1460-9568.2011.07646.x.

PMID:
21496122
16.

Role of Toll like receptor 4 signaling pathway in the secondary damage induced by experimental spinal cord injury.

Impellizzeri D, Ahmad A, Di Paola R, Campolo M, Navarra M, Esposito E, Cuzzocrea S.

Immunobiology. 2015 Sep;220(9):1039-49. doi: 10.1016/j.imbio.2015.05.013. Epub 2015 May 11.

PMID:
25990044
17.

Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia.

Siracusa R, Impellizzeri D, Cordaro M, Crupi R, Esposito E, Petrosino S, Cuzzocrea S.

Front Neurol. 2017 Jun 6;8:233. doi: 10.3389/fneur.2017.00233. eCollection 2017.

18.

Tempol reduces injury area in rat model of spinal cord contusion injury through suppression of iNOS and COX-2 expression.

Quan HH, Kang KS, Sohn YK, Li M.

Neurol Sci. 2013 Sep;34(9):1621-8. doi: 10.1007/s10072-013-1295-y. Epub 2013 Jan 25.

PMID:
23354604
19.

KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice.

Cordaro M, Paterniti I, Siracusa R, Impellizzeri D, Esposito E, Cuzzocrea S.

Mol Neurobiol. 2017 May;54(4):2415-2427. doi: 10.1007/s12035-016-9827-0. Epub 2016 Mar 10.

PMID:
26960330
20.

Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats.

Sayd A, Antón M, Alén F, Caso JR, Pavón J, Leza JC, Rodríguez de Fonseca F, García-Bueno B, Orio L.

Int J Neuropsychopharmacol. 2014 Dec 28;18(6). pii: pyu111. doi: 10.1093/ijnp/pyu111. Erratum in: Int J Neuropsychopharmacol. 2016;19(3). pii: pyw004. doi: 10.1093/ijnp/pyw004.

Supplemental Content

Support Center